



US 20180369297A1

(19) **United States**

(12) **Patent Application Publication**

Karlsson et al.

(10) **Pub. No.: US 2018/0369297 A1**

(43) **Pub. Date: Dec. 27, 2018**

(54) **TREATMENT OF INTRAHEPATIC
CHOLESTASIS AND RELATED LIVER
DISEASES**

(71) Applicant: **METABOGEN AB**, Gothenburg (SE)

(72) Inventors: **Fredrik Karlsson**, Molndal (SE); **Bo Mollstam**, Lerum (SE)

(21) Appl. No.: **15/781,595**

(22) PCT Filed: **Dec. 14, 2016**

(86) PCT No.: **PCT/EP2016/080941**

§ 371 (c)(1),

(2) Date: **Jun. 5, 2018**

Related U.S. Application Data

(60) Provisional application No. 62/266,771, filed on Dec. 14, 2015.

Publication Classification

(51) **Int. Cl.**

A61K 35/745 (2006.01)

A61P 1/16 (2006.01)

A61P 1/18 (2006.01)

A61K 31/733 (2006.01)

(52) **U.S. Cl.**

CPC *A61K 35/745* (2013.01); *A61P 1/16* (2018.01); *A61P 17/04* (2018.01); *A61K 31/733* (2013.01); *A61P 1/18* (2018.01)

(57) **ABSTRACT**

The invention is directed to a method of treating or reducing the risk of intrahepatic cholestasis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising at least one bacterial species or strain comprising bile acid deconjugation/hydrolysis activity and/or 7-epimerization activity, thereby treating or reducing the risk of intrahepatic cholestasis in a subject in need thereof. Compositions for use in such methods are also provided.

TREATMENT OF INTRAHEPATIC CHOLESTASIS AND RELATED LIVER DISEASES

FIELD OF THE INVENTION

[0001] The present invention relates generally to medicine. More specifically, the invention relates to methods and products for probiotic interventions in mammals at risk for developing or having intrahepatic cholestasis of pregnancy.

BACKGROUND OF THE INVENTION

[0002] Intrahepatic Cholestasis of Pregnancy (ICP) is a disease that appears in the later stage of pregnancy with itching (pruritus) and fetal complications. It is the most prevalent pregnancy-specific liver disease and is associated with an increased risk of adverse fetal outcomes, including preterm labor and intrauterine death. Further, ICP is associated with an increased risk for pre-eclampsia, thyroid disease, diabetes and cancer. The following factors may increase a woman's risk of developing ICP:

- [0003] A close relative who had ICP.
- [0004] Experienced ICP in previous pregnancies.
- [0005] Being pregnant with twins, triplets etc. (multiple pregnancy)
- [0006] Having a history of liver damage.
- [0007] In-vitro fertilization (IVF) treatment.

[0008] The diagnostic criteria for ICP have varied over time and have included clinical jaundice, severity of pruritus and elevated bile acid levels. Today, the most appropriate laboratory parameter for diagnosis of ICP is elevation of bile acids ($\geq 10 \mu\text{mol/L}$) in combination with unexplained pruritus.

[0009] An available pharmacologic treatment for patients with ICP is ursodeoxycholic acid (UDCA). In a double-blind, placebo-controlled trial for women with ICP, the effects of UDCA treatment was studied. 130 women were randomized to UDCA treatment, dexamethasone treatment or placebo treatment. Pruritus and biochemical markers of cholestasis were analyzed at inclusion and after 3 weeks of treatment. Also fetal complications were registered. UDCA treatment improved some biochemical markers of ICP irrespective of disease severity, but a significant relief from pruritus and marked reduction of serum bile acids were only found in patients with severe ICP (bile acid levels $\geq 40 \mu\text{mol/L}$) and therefore there is a need for a more effective treatment. The present invention is intended to solve this problem.

SUMMARY OF THE INVENTION

[0010] The present invention relates to methods, uses and products (or compositions) for probiotic interventions in mammals at risk for developing or having intrahepatic cholestasis, including but not limited to intrahepatic cholestasis of pregnancy.

[0011] The present invention relates to methods, uses and products (or compositions) for probiotic interventions in mammals based on certain bacteria with desirable characteristics.

[0012] The invention discloses a method for modulating serum bile acid level in a mammal at risk for developing or having intrahepatic cholestasis of pregnancy.

[0013] The invention discloses a method for reducing pruritus in a mammal having intrahepatic cholestasis of

pregnancy. The invention further discloses a method for preventing pruritus in a mammal at risk for developing intrahepatic cholestasis of pregnancy.

[0014] The invention relates to methods for reducing and/or preventing the risk for the fetus in mammals at risk for developing or having intrahepatic cholestasis of pregnancy.

[0015] A primary object of the invention is to provide bacteria, e.g. probiotic bacteria, with the capability of bile acid deconjugation/hydrolysis and/or 7-epimerisation for use in the treatment of intrahepatic cholestasis of pregnancy (and other diseases as described elsewhere herein). In some embodiments, two or more different bacterial strains are used that together exert said capabilities. As epimerization includes two reactions, oxidation of the 7α -hydroxyl group by a 7α -hydroxysteroid dehydrogenase (HSDH) and stereo-specific reduction of the 7-keto functionality by a 7β -HSDH, it is another object of the invention, to choose two different probiotic bacterial strains or species, one comprising 7α -HSDH enzyme activity and the other one comprising 7β -HSDH enzyme activity to obtain the 7-epimerization reaction. In a further object of the invention a sulphate reducing probiotic bacteria can also be used in the treatment. In some embodiments, the invention comprises the use of several bacterial strains that together exert the capabilities described above. Alternatively, a single bacterial strain can be used.

[0016] The vast majority of naturally occurring bile salts are conjugated, most commonly to glycine or taurine. Such conjugated bile salts when present in the small intestine are actively reabsorbed through the apical sodium-dependent bile transporter (ASBT) located in the ileum. Deconjugated bile acids are not actively reabsorbed in this way and a proportion of these will eventually be excreted in the feces. In addition, deconjugated bile acids are more hydrophobic than their conjugated counterparts, thus are less reabsorbed through the intestine, also resulting in higher excretion into the feces. In other words, bile acid deconjugation (also referred to herein as bile acid hydrolysis) reduces enterohepatic recirculation of bile acid and thereby reduces the total bile acid pool, including for example serum or plasma levels of bile acid. Glycine conjugates are generally present in a higher proportion (3:1) to taurine conjugates in human bile. Therefore, in some aspects, the invention includes administration of a bacterial strain or species that comprises hydrolyzing enzyme activity. In some embodiments, the hydrolyzing enzyme or bile acid deconjugation activity of the bacterial strain may have a higher affinity for glycine conjugates than e.g. taurine conjugates. Thus, whilst not wishing to be bound by theory, it is believed that it is the ability of bacterial strains to achieve or stimulate bile acid deconjugation which results in reduced reabsorption or increased excretion of said bile acids, which in turn results in reduced serum levels of bile acids. Strains with this activity thus find therapeutic utility in diseases or disorders characterised by increased serum bile acid levels.

[0017] In some aspects, the hydrolyzing bacterial strain (or strain comprising bile acid deconjugation activity) may comprise a strain of *Bifidobacterium*, for example *Bifidobacterium longum*, for example *Bifidobacterium longum* ATCC BAA-999.

[0018] In another object of the invention, a hydrolyzing bifidobacteria (or other bacterial species or strain comprising bile acid deconjugation/hydrolysis activity as described

elsewhere herein) may be administered to a mammal together with a prebiotic, for example which enhances the activity of the bifidobacteria (or other bacteria). A prebiotic can be, but is not limited to, inulin, starch, fructooligosaccharides (FOS) or galactooligosaccharides (GOS).

[0019] Ursodeoxycholic acid (UDCA) has been used for the treatment of ICP for some time. Absorption of ursodeoxycholic acid is slow and incomplete due to its poor solubility and it competitively inhibits the absorption of other bile acids. Several species of bacteria can convert chenodeoxycholic acid to ursodeoxycholic acid through a 7-epimerizing reaction. So instead of the addition of ursodeoxycholic acid we utilize the bacteria's enzyme activity and capability to shift the composition of the bile acids. This will for example lead to a reduced amount of bile acids in the blood stream. Also reduced levels of lithocholic acid may be produced. Epimerization includes two reactions, oxidation of the 7 α -hydroxyl group by a 7 α -hydroxysteroid dehydrogenase (HSDH) and stereospecific reduction of the 7-keto functionality by a 7 β -HSDH.

[0020] Bacterial strains having 7-epimerizing capabilities include but are not limited to such bacteria as *Clostridium*, e.g. *Clostridium baratii*, e.g. *Clostridium baratii* ATCC 27638. In another object of the invention two different bacterial species may be chosen, one capable of stereospecific reduction of the 7-keto functionality by a 7 β -HSDH and the other having 7 α -HSDH enzyme activity. Non-limiting examples of probiotic bacterial strains having 7 α -HSDH enzyme activity include species of *Bacteroides*, for example *Bacteroides fragilis* (e.g. *Bacteroides fragilis* ATCC 25285) and *Bacteroides thetaiotaomicron* (e.g. *Bacteroides thetaiotaomicron* DSM 2079) and a non-limiting example of a strain having 7 β -HSDH enzyme activity include species of *Collinsella*, for example *Collinsella aerofaciens* (e.g. *Collinsella aerofaciens* ATCC 25986).

[0021] As more bile acids may be in a deconjugated form due to administration of a hydrolysing bacterial strain, an increase in free taurine concentration may take place. A further object of the invention is therefore to administer a sulfate reducing bacteria, thereby avoiding the detrimental effects of the increase in taurine. Such sulfate reducing bacteria include, but are not limited to species of *Desulfovibrio*, for example *Desulfovibrio piger* (e.g. *Desulfovibrio piger* DSM 32187). In some embodiments, the use of such sulfate reducing bacteria is preferred.

DETAILED DESCRIPTION OF THE INVENTION

[0022] The present invention thus relates generally to the use of probiotic bacterial strains to treat or prevent (reduce the risk of) intrahepatic cholestasis. Such treatments are based on the selection of one or more bacterial strains (or species) which have bile acid deconjugation (or hydrolysis) activity and/or 7-epimerization activity. Preferably the one or more strains used in the therapeutic methods will have both bile acid deconjugation and 7-epimerization activity, either together in the same strain or provided by way of a combination of strains. Such one or more strains can be used to treat or prevent (reduce the risk of) other diseases as described elsewhere herein. Such therapeutic treatments are generally based on the ability of said bacterial strains to modulate and preferably reduce serum bile acid level. Thus,

methods of modulating (e.g. reducing) bile acid level, e.g. bodily fluid bile acid level such as serum bile acid level, are also provided.

[0023] The foregoing and other aspects of the present invention will now be described in more detail with respect to the description and methodologies provided herein. It should be appreciated that the invention may be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.

[0024] The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.

[0025] As used in the description of the embodiments of the invention, the singular forms "a," "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. Also, as used herein, "and/or" refers to and encompasses any and all possible combinations of one or more of the associated listed items.

[0026] Furthermore, the term "about," as used herein when referring to a measurable value such as an amount of a compound, dose, time, temperature, and the like, refers to variations of 20%, 10%, 5%, 1%, 0.5%, or even 0.1% of the specified amount. When a range is employed (e.g., a range from x to y) it is meant that the measurable value is a range from about x to about y, or any range therein, such as about x_1 to about y_1 , etc.

[0027] It will be further understood that the terms "comprises" and/or "comprising," when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof.

[0028] In some embodiments of the invention, the compositions for example do not contain any active ingredients or components beyond those specified, e.g. consist of those active ingredients or components. Thus, for example, where compositions comprising particular bacterial strains are described herein, in some embodiments the compositions will consist of those bacterial strains and not contain any other bacterial strains. In other embodiments such compositions will not contain any further or additional active ingredients or components.

[0029] Unless otherwise defined, all terms, including technical and scientific terms used in the description, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0030] "Effective amount" or dosage as used herein refers to an amount of a bacterial composition of the invention that is sufficient to produce a desired effect, which can be a therapeutic and/or beneficial effect. The effective amount or dosage will vary with the age, general condition of the subject, the severity of the condition being treated, the particular composition administered, the duration of the treatment, the nature of any concurrent treatment, the pharmaceutically acceptable carrier used, and like factors within the knowledge and expertise of those skilled in the art. As appropriate, an "effective amount" or dosage in any indi-

vidual case can be determined by one of skill in the art by reference to the pertinent texts and literature and/or by using routine experimentation.

[0031] By the term “treat,” “treating,” or “treatment of” (and grammatical variations thereof) it is meant that the severity of the subject’s condition is reduced, at least partially improved or ameliorated and/or that some alleviation, mitigation or decrease in at least one clinical symptom is achieved and/or there is a delay in the progression of the disease or disorder.

[0032] As will be clear from the disclosure elsewhere herein, the methods and uses of the prevent invention are suitable for reducing the risk of disease or prevention of disease as well as active treatment of diseases (for example treatment of pre-existing disease). Thus, prophylactic treatment is also encompassed by the invention.

[0033] Such preventative (or protective) aspects can conveniently be carried out on healthy or normal or at risk subjects and can include both complete prevention and significant prevention. Similarly, significant prevention can include the scenario where severity of disease or symptoms of disease is reduced (e.g. measurably or significantly reduced) compared to the severity or symptoms which would be expected if no treatment is given.

[0034] A “therapeutically effective” amount as used herein is an amount that is sufficient to treat (as defined herein) the subject. Those skilled in the art will appreciate that the therapeutic effects need not be complete or curative, as long as some benefit is provided to the subject.

[0035] As used herein, the terms “modulating,” “modulate,” “modulates” or grammatical variations thereof, means an alteration, for example in the amount or level of a component in a bodily fluid (e.g., blood, serum, and the like) of a subject, by administering to the subject a therapeutically effective amount of a composition comprising at least one bacterial, e.g. probiotic bacterial, species or strain, thereby increasing or reducing the amount or level of the component. In embodiments of the invention where bodily fluid, e.g. blood or serum, bile acid levels are modulated, then preferably the amount or level of bile acid is reduced or decreased.

[0036] The terms “increase,” “increasing,” “increased,” “higher”, “enhance,” “enhanced,” “enhancing,” and “enhancement” (and grammatical variations thereof), as used herein, describe an elevation, for example, an elevation in the amount or level of a component in a bodily fluid (e.g., blood, serum, and the like) of a subject (e.g., an elevation of at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 75%, 100%, 125%, 150%, 175%, 200%, 350%, 300%, 350%, 400%, 450%, 500% or more). This increase in expression, amount or level, can be observed by, for example, comparing the amount or level of a component in a bodily fluid of a subject to the amount or level of the same component in the bodily fluid of a control subject that, for example, has not been administered a therapeutically effective amount of a composition comprising at least one bacterial, e.g. probiotic bacterial, species or strain as described herein.

[0037] As used herein, the terms “reduce,” “reduced,” “reducing,” “reduction,” “diminish,” “suppress,” and “decrease” (and grammatical variations thereof), describe, for example, a decrease in the amount or level of a component in a bodily fluid (e.g., blood, serum, and the like) of a subject, e.g. as compared to a control as described herein. Thus, this decrease in amount or level can be observed by,

for example, comparing the amount or level of a component in a bodily fluid of a subject to the amount or level of the same component in the bodily fluid of a control subject that, for example, has not been administered a therapeutically effective amount of a composition comprising at least one probiotic bacterial species or strain as described herein. In preferred embodiments of the invention, decreases in bile acid levels in a body fluid of a subject (e.g. serum bile acid levels), e.g. compared to a control subject, are obtained.

[0038] Appropriate control subjects would readily be identified by a person skilled in the art and might include a non-treated or placebo-treated subject (or a population thereof), or might include a level of a particular parameter, e.g. bile acid level, in the same individual subject measured at an earlier time point, such as before treatment (e.g. comparison with a “baseline” level in that subject). Preferably the increase or decrease (as appropriate) will be significant, for example clinically or statistically significant, for example with a probability value of ≤ 0.05 , when compared to an appropriate control level or value.

[0039] A “subject” of the invention includes any animal that has or is susceptible to intrahepatic cholestasis (or any other disease or disorder for treatment by the present invention as described elsewhere herein). In some embodiments, the subject can be a mammal. Mammalian subjects include but are not limited to humans, non-human primates (e.g., gorilla, monkey, baboon, and chimpanzee, etc.), dogs, cats, goats, horses, pigs, cattle, sheep, and the like, and laboratory animals (e.g., rats, guinea pigs, mice, gerbils, hamsters, and the like). Suitable subjects include both males and females and subjects of any age, including embryonic (e.g., in utero or in ovo or fetal), infant, juvenile, adolescent, adult and geriatric subjects. In some embodiments, a subject of this invention is a human. In representative embodiments, the subject is a human female. In other representative embodiments, the subject is a pregnant human female, and/or her fetus or unborn baby which can suffer adverse effects from intrahepatic cholestasis (or other diseases or disorders as described herein).

[0040] A “subject” or a “subject in need” of the methods of the invention can be a subject known to have or suspected of having or at risk of developing cholestasis, e.g. extrahepatic cholestasis or intrahepatic cholestasis. In representative embodiments, a subject or subject in need can be a subject known to have or suspected of having or at risk of developing intrahepatic cholestasis of pregnancy (ICP). A subject or subject in need thereof may also be a subject known to have, suspected of having, or at risk of developing pruritus (in particular pruritus arising as a symptom of intrahepatic cholestasis, e.g. ICP). In some embodiments, a subject or subject in need can be a subject that is known to have, is suspected of having, or is at risk of developing gall stones, biliary dyspepsia, primary biliary cirrhosis, primary sclerosing cholangitis, chronic active hepatitis, hepatitis C and/or other related liver diseases.

[0041] The methods and uses of the invention can also be used to treat, alleviate (reduce or relieve) or prevent (reduce the risk of) symptoms or side effects of the above diseases, for example pruritus in the case of intrahepatic cholestasis or ICP (or indeed any other disease as described herein).

[0042] In preferred embodiments, a subject or subject in need is a subject known to have, or suspected of having, or at risk of developing intrahepatic cholestasis, in particular intrahepatic cholestasis of pregnancy. More generally, the

methods of the invention can be used to treat or reduce the risk of any disease associated with or characterised by altered and preferably increased bile acid level, in particular serum bile acid level, e.g. serum bile acid levels of ≥ 10 $\mu\text{mol/L}$ (e.g. 10 to 39 $\mu\text{mol/L}$), or ≥ 40 $\mu\text{mol/L}$ (e.g. 40 to 79 $\mu\text{mol/L}$), or ≥ 80 $\mu\text{mol/L}$. In some embodiments, subjects with serum bile acid levels of ≥ 10 $\mu\text{mol/L}$ and < 40 $\mu\text{mol/L}$ are preferred.

[0043] As used herein the term “concomitant administration” or “combination administration” of a composition, therapeutic agent or known drug (e.g., prebiotic) with a bacterial composition of the present invention means administration of a known medication or drug and, in addition, the one or more bacterial species or strains of the invention at such time that both the known drug and the bacterial species or strain will have a therapeutic effect. In some cases, this therapeutic effect will be synergistic. Such concomitant administration can involve concurrent (i.e., at the same time, in parallel at the same time), prior, or subsequent administration (e.g., sequential) of the known drug with respect to the administration of a bacterial composition of the present invention. Such concomitant or combination administration may also refer to administration of a compound (e.g. a bacterial strain of species) of the invention through different administrative routes separately (e.g., at least about 2 or more hours apart), sequentially (e.g., within about 2 hours, e.g., about 15 sec, 30 sec, 45 sec, 1 min, 2, min, 3 min, 4 min, 5 min, 6 min, 7 min, 8 min, 9 min, 10 min, 11 min, 12 min, 13 min, 14 min, 15 min, 16 min, 17 min, 18 min, 19 min, 20 min, 21 min, 22 min, 23 min, 24 min, 25 min, 26 min, 27 min, 28 min, 29 min, 30 min, 35 min, 40 min, 45 min, 50 min, 55 min, 60 min, 65 min, 70 min, 75 min, 80 min, 85 min, 90 min, 95 min, 100 min, 105 min, 110 min, 115 min, and the like, and any range or value therein) and/or in parallel at the same time (e.g., concurrently) in order to achieve effective amount or dosage. A person of skill in the art, would have no difficulty determining the appropriate timing, sequence and dosages of administration for particular drugs and bacterial compositions of the present invention.

[0044] “Probiotics” are live microorganisms that, when administered in adequate amounts, confer a health benefit to the host.

[0045] Intrahepatic cholestasis of pregnancy (ICP) usually occurs during the last trimester of pregnancy. It may trigger severe pruritus, especially on the hands and feet (often without rash), but is rarely of concern for the mother’s long-term health. However it may cause severe complications for the fetus such as pre-term (premature) birth, fetal distress, inhaling meconium during birth resulting in breathing difficulties (e.g. meconium aspiration syndrome) and also intrauterine death or stillbirth. Thus, the methods and uses of the invention can treat or reduce the risk of such complications in the fetus as well as treating or reducing the risk of ICP and symptoms thereof in the mother. Women that previously have experienced ICP have a higher risk for developing ICP during their later pregnancies; also women with relatives that have had ICP have an increased risk for developing ICP. Other risk factors associated with developing ICP are multiple pregnancies, a history of liver damage and in-vitro fertilization (IVF) treatment. Such women are further examples of subjects or subjects in need (e.g. at risk subjects) that can be treated in accordance with the present invention.

[0046] The diagnostic criteria for ICP have varied over time and have included clinical jaundice, severity of pruritus and elevated bile acid levels, generally in the blood, e.g. serum or plasma. Today, the most appropriate laboratory parameter for diagnosis of ICP is elevation of bile acids (≥ 10 $\mu\text{mol/L}$) in combination with unexplained pruritus. The incidence of ICP was found to be 1.5% in a prospective cohort study in Sweden. A mild form of ICP (81% of ICP patients) can be defined as bile acid levels < 40 $\mu\text{mol/L}$ (but ≥ 10 $\mu\text{mol/L}$) and a severe form of ICP (19% of ICP patients) defined as bile acid levels ≥ 40 $\mu\text{mol/L}$, which is also associated with a higher rate of fetal complications. The probability of fetal complications increased by 1% -2% per $\mu\text{mol/L}$ of total bile acid increase. Any forms of ICP can be treated with the methods of the present invention. For example, in a preferred embodiment, mild forms of ICP as defined above are treated. In other embodiments severe forms of ICP as defined above are treated.

[0047] In the last trimester, the pregnancy hormones, particularly progesterone, cause muscular tissue to relax, which will prepare the birth canal prior to delivery. This can also affect the proper function of the gallbladder, which has the purpose of storing bile.

[0048] Bile acids/salts play a critical role in activating digestive enzymes and solubilizing fats and fat-soluble vitamins and are involved in liver, biliary, and intestinal disease. Bile acids are synthesized in the liver by a multistep, multiorganelle pathway. Bile salts are excreted by the hepatocytes into the canaliculi to form bile. The canaliculi drain into the right and left hepatic ducts and the bile flows to the gallbladder. Bile is released from the gallbladder and travels to the duodenum, where it contributes to the metabolism and degradation of fat.

[0049] The common bile acids differ primarily in the number and orientation of hydroxyl groups on the sterol ring. The term, primary bile acid refers to those synthesized de novo by the liver. In humans, the primary bile acids include cholic acid (3 α , 7 α , 12 α -trihydroxy-5 β -cholanolic acid) (“CA”) and chenodeoxycholic acid (3 α , 7 α -dihydroxy-5 β -cholanolic acid) (“CDCA”). Dehydroxylation of these bile acids by intestinal bacteria produces the more hydrophobic secondary bile acids, deoxycholic acid (3 α , 12 α -dihydroxy-5 β -cholanolic acid) (“DCA”) and lithocholic acid (3 α -hydroxy-5 β -cholanolic acid) (“LCA”). These four bile acids CA, CDCA, DCA, and LCA, generally constitute greater than 99 percent of the bile salt pool in humans. Secondary bile acids that have been metabolized by the liver are sometimes denoted as tertiary bile acids.

[0050] Keto-bile acids are produced secondarily in humans as a consequence of oxidation of bile acid hydroxyl groups, particularly the 7-hydroxyl group, by colonic bacteria. However, keto-bile acids are rapidly reduced by the liver to the corresponding α or β -hydroxy bile acids. For example, the corresponding keto bile acid of a CDCA is 7-keto lithocholic acid and one of its reduction products with the corresponding beta-hydroxy bile acid is ursodeoxycholic acid (3 α -7 β -dihydroxy-5 β -cholanolic acid) (“UDCA”), a tertiary bile acid.

[0051] UDCA, a major component of bear bile, has been used as a pharmaceutical agent for the treatment of and the protection against many types of liver disease for a little over 70 years. Its medicinal uses include the dissolution of radiolucent gall stones, the treatment of biliary dyspepsia, primarily biliary cirrhosis, primary sclerosing cholangitis,

chronic active hepatitis and hepatitis C. In other mammalian species, bile acids containing a 6β -hydroxyl group, which are found in rats and mice, are known as muricholic acid, and 6α -hydroxy bile acids produced by swine are termed hyocholic acid and hyodeoxycholic acids. 23-hydroxy bile acids of aquatic mammals are known as phocecholic and phocedeoxycholic acids.

[0052] Typically, more than 99 percent of naturally occurring bile salts secreted into human bile are conjugated. Conjugates are bile acids in which a second organic substituent (e.g. glycine, taurine, glucuronate, sulfate or, rarely, other substituents) is attached to the side chain carboxylic acid or to one of the ring hydroxyl groups via an ester, ether, or amide linkage. Conjugated bile acids are less cytotoxic than free bile acids.

[0053] Around 95% of bile salts that are released into the small intestine are actively reabsorbed. Bile salt reabsorption, in particular of the conjugated bile acids, occurs via the apical sodium-dependent bile transporter (ASBT) present in the brush border membrane of the enterocyte. Once bile salts reach the basolateral membrane they are transported into the blood. A small percentage of the bile salts are not actively reabsorbed and undergo deconjugation by the intestinal microbiota before either being absorbed or converted into secondary bile acids, deoxycholate (DCA, from cholate) and lithocholate and ursodeoxycholate (LCA and UDCA, from chenodeoxycholate). Secondary bile acids are either passively absorbed or are excreted in the feces. The absorbed primary and secondary bile acids and salts are transported back to the liver where most, but not all, are actively transported into hepatocytes. Once in the liver the bile acids are re-conjugated and then re-secreted together with newly synthesized bile salts. This overall process constitutes one cycle of what is called the enterohepatic circulation. Within the intestinal lumen, bile acid concentrations vary, with the bulk of the reuptake occurring in the distal intestine. Bile acids/salts alter the growth of bacterial flora in the gut. The bile acid pool contains about 2-4 g of bile acids and this pool is recycled via the enterohepatic circulation on the order of six to ten times each day. Of the total bile salt pool, around 0.2-0.6 g are excreted in the feces each day. This lost fraction of bile salts is replenished via de novo hepatic bile acid synthesis from cholesterol.

[0054] The present invention is based on the principle that combinations of certain bacteria could decrease the serum bile acid level and relieve pruritus in women suffering from intrahepatic cholestasis of pregnancy. Thus, the present invention relates to methods, uses and products for probiotic interventions in mammals at risk for developing or having or suspected of having intrahepatic cholestasis, including but not limited to intrahepatic cholestasis of pregnancy. The treatment or prevention of other diseases is also provided as described elsewhere herein. The invention herein can be carried out in various ways, forms and embodiments and is not limited to what is described herein.

[0055] In particular embodiments of the invention a method for modulating (e.g. reducing) serum bile acid level and a method for treating or reducing pruritus or the risk of pruritus in a subject, e.g. mammal, preferably having intrahepatic cholestasis, are provided, including but not limited to mammals or subjects at risk for developing or having or suspected of having intrahepatic cholestasis of pregnancy.

[0056] In one embodiment, probiotic bacteria are administered to said subject, e.g. mammal. The probiotic bacteria

having the capability of bile acid deconjugation/hydrolysis and 7-epimerisation are preferably for use in the treatment of intrahepatic cholestasis of pregnancy. In related embodiments, the probiotic bacteria can comprise one bacterial strain or species having the capability of bile acid deconjugation/hydrolysis and/or 7-epimerisation, or a combination of several bacterial strains or species (i.e., more than one, e.g., 2, 3, 4, 5, 6 and the like bacterial species or strains) that together exert or provide the capabilities described above.

[0057] As described elsewhere herein, deconjugated bile acids are not actively reabsorbed by the ASBT and a proportion of these will eventually be excreted in the faeces. In addition, deconjugated bile acids are more hydrophobic than their conjugated counterparts, thus are less reabsorbed through the intestine, also resulting in higher excretion into the feces. In other words, bile acid deconjugation reduces enterohepatic recirculation of bile acid, thereby reducing the total bile acid pool. Absorption of ursodeoxycholic acid (UDCA) is slow and incomplete due to poor solubility and it competitively inhibits the absorption of other bile acids. Several species of bacteria can convert chenodeoxycholic acid to ursodeoxycholic acid through a 7-epimerizing reaction. Epimerization includes two reactions, oxidation of the 7α -hydroxyl group by a 7α -hydroxysteroid dehydrogenase (HSDH) and stereospecific reduction of the 7-keto functionality by a 7β -HSDH.

[0058] In one embodiment, a combination of probiotic bacteria strains can comprise one strain with capability of bile acid deconjugation/hydrolysis and another strain having the capability of 7-epimerisation. In some embodiments, the hydrolysing bacterial strain can comprise *Bifidobacterium*, e.g. *Bifidobacterium longum*, e.g. *Bifidobacterium longum* ATCC BAA-999. Glycine conjugates are generally higher in proportion (3:1) to taurine conjugates in human bile; therefore, in some embodiments, the bile acid deconjugation/hydrolysis activity of the bacterial strain may have a higher affinity or activity for glycine conjugates, e.g. than taurine conjugates. In some embodiments, a bacterial strain having 7-epimerizing enzyme activity can comprise *Clostridium*, e.g. *Clostridium baratii*, e.g. *Clostridium baratii* ATCC 27638.

[0059] In another embodiment, said probiotic bacterial strain combination can comprise one strain and/or species comprising the enzyme activity of bile acid deconjugation/hydrolysis and more than one strain and/or species to provide the 7-epimerizing enzyme activity, for example another strain and/or species comprising the enzyme activity of 7α -HSDH and yet another strain and/or species comprising the enzyme activity of 7β -HSDH. Epimerization of bile acid hydroxyl groups is the reversible change in stereochemistry from α to β configuration (or vice versa). In the context of the present invention, 7-epimerization activity can result in the reversible change of CDCA to UDCA. The extent of the reversible oxidation and reduction of bile acid hydroxyl groups by HSDH depends in part on the redox potential of the environment in the gut. Higher redox potential, favoring oxidation by the 7α -HSDH, is found on the mucosal surface and a lower redox potential, favoring reduction by the 7β -HSDH, is found in the intestinal lumen. When using two different strains (one with 7α -HSDH enzyme activity and the other one with 7β -HSDH enzyme activity) for obtaining the 7-epimerizing reaction the advantage of using the varying redox potential is utilized. In some embodiments, a hydrolysing bacterial strain/species can comprise *Bifidobac-*

terium, e.g. *Bifidobacterium longum*, e.g. *Bifidobacterium longum* ATCC BAA-999. In some embodiments, exemplary bacterial species or strains having 7 α -HSDH enzyme activity can include *Bacteroides*, e.g. *Bacteroides fragilis*, e.g. *Bacteroides fragilis* ATCC 25285 and *Bacteroides thetaiotaomicron*, e.g. *Bacteroides thetaiotaomicron* DSM 2079. *Collinsella*, e.g. *Collinsella aerofaciens*, e.g. *Collinsella aerofaciens* ATCC 25986, is a nonlimiting example of a strain or species with 7 β -HSDH enzyme activity.

[0060] In some embodiments, as more bile acids may be in a deconjugated form, due to administration of a hydrolysing bacterial strain/species, an increase in free taurine concentration may possibly take place. Some pathogenic bacteria have the unique capability of metabolizing taurine to hydrogen sulfide, H₂S, which is highly toxic. Thus, in a further embodiment of the invention, a sulfate reducing bacteria can be administered to outcompete the metabolic activity of such pathogenic bacteria, thus avoiding negative effects of the released taurine. *Desulfovibrio*, e.g. *Desulfovibrio piger*, e.g. *Desulfovibrio piger* DSM 32187, is one example of a strain with sulfate reducing capabilities.

[0061] In one embodiment of the invention, a nonlimiting example of a probiotic bacteria strain/species combination can be *Bifidobacterium*, *Bacteroides* and *Collinsella*, or *Bifidobacterium* and *Clostridium*. Examples of appropriate bacteria include one or more or all of (e.g. 2 or 3 of) *Bifidobacterium longum*, *Bacteroides fragilis*, and *Collinsella aerofaciens*, or one or more or all of (e.g. 2 or 3 of) *Bifidobacterium longum*, *Bacteroides thetaiotaomicron*, and *Collinsella aerofaciens*. Examples of appropriate bacteria also include one or both of *Bifidobacterium longum* and *Clostridium baratii*. Any of these combinations may further comprise *Desulfovibrio* bacteria, e.g. *Desulfovibrio piger*.

[0062] Preferred examples of strains to be used in the above combinations are one or more or all of (e.g. 2 or 3 or 4 of) *Bifidobacterium longum* ATCC BAA-999, *Bacteroides fragilis* ATCC 25285, *Collinsella aerofaciens* ATCC 25986, *Bacteroides thetaiotaomicron* DSM 2079, *Clostridium baratii* ATCC 27638, or *Desulfovibrio piger* DSM 32187.

[0063] In one embodiment of the invention, a nonlimiting example of a probiotic bacteria strain/species combination can be *Bifidobacterium longum* ATCC BAA-999, *Bacteroides fragilis* ATCC 25285, *Collinsella aerofaciens* ATCC 25986 and *Desulfovibrio piger* DSM 32187. In further embodiment of the invention, a nonlimiting example of a probiotic bacterial combination comprises *Bifidobacterium longum* ATCC BAA-999, *Bacteroides thetaiotaomicron* DSM 2079, *Collinsella aerofaciens* ATCC 25986 and *Desulfovibrio piger* DSM 32187. In yet another embodiment of the invention, a probiotic bacteria combination comprises *Bifidobacterium longum* ATCC BAA-999, *Clostridium baratii* ATCC 27638 and *Desulfovibrio piger* DSM 32187. Other examples would be these combinations without *Desulfovibrio piger* DSM 32187.

[0064] Compositions or products or formulations or kits comprising the above combinations of bacterial strains or species provide a yet further aspect of the invention. Such compositions may take the form of pharmaceutical compositions or nutritional compositions. Some exemplary compositions are provided in the Examples.

[0065] In a related embodiment of the invention, the bifidobacteria (or other bacteria as discussed above) may be administered to a mammal together with a prebiotic which may enhance the activity of the bifidobacteria (or other

bacteria). A prebiotic can include but is not limited to inulin. Other examples of prebiotics are described elsewhere herein.

[0066] In one embodiment of the invention, a probiotic bacteria strain or strain combination as described herein can be for use in mammals (or subjects) at risk for developing ICP. Risk factors include previous experience of ICP, relatives that have had ICP (i.e. genetic factors), multiple pregnancies, history of liver damage and in-vitro fertilization (IVF) treatment. In some embodiments, the administration can be about one, two or three times/day and treatment may start when the mammal becomes pregnant. The administration may also start when the mammal is planning to get pregnant, if said mammal is at risk of developing ICP. In another embodiment, the administration can be about one, two or three times/day and treatment may start in the second trimester (around week 13 of pregnancy).

[0067] In another embodiment of the invention, a probiotic bacteria strain or strain combination as described herein can be for use in a mammal (or subject) having ICP. In some embodiments, the treatment group comprises a mammal having bile acids levels that exceed 10 $\mu\text{mol/L}$ (or 40 $\mu\text{mol/L}$ or 80 $\mu\text{mol/L}$) and unexplained pruritus, or patients with mild or severe ICP as described elsewhere herein. In some embodiments, the administration can be one, two or three times/day and last for one, two or three months or as long as said mammal is pregnant or until the baby is born.

[0068] In some embodiments of the invention, a probiotic bacteria strain or strain combination as described herein can be for use in a mammal (or subject) at risk for developing or having ICP (e.g. ICP subject groups as defined elsewhere herein) in order to decrease the risk for the fetus and/or baby. The decreased risk for the fetus can include but is not limited to a decreased risk for pre-term birth, inhaling meconium during birth resulting in breathing difficulties and/or also intrauterine death or stillbirth.

[0069] In some embodiments of the invention, a probiotic bacteria strain or strain combination as described herein can be for use in diseases including but not limited to cholestasis (e.g. extrahepatic or intrahepatic cholestasis), intrahepatic cholestasis (e.g., intrahepatic cholestasis of pregnancy), gall stones, the treatment of biliary dyspepsia, primarily biliary cirrhosis, primary sclerosing cholangitis, chronic active hepatitis and hepatitis C and/or other related liver diseases. In some such embodiments, the treatment group comprises a mammal having increased bile acid levels, e.g. bile acids levels, in particular serum bile acid levels, that exceed 10 $\mu\text{mol/L}$ (or 40 $\mu\text{mol/L}$ or 80 $\mu\text{mol/L}$), e.g. serum bile acid levels of ≥ 10 $\mu\text{mol/L}$ (e.g. 10 to 39 $\mu\text{mol/L}$ or ≥ 10 $\mu\text{mol/L}$ and < 40 $\mu\text{mol/L}$), or ≥ 40 $\mu\text{mol/L}$ (e.g. 40 to 79 $\mu\text{mol/L}$ or ≥ 40 $\mu\text{mol/L}$ and < 80 $\mu\text{mol/L}$), or ≥ 80 $\mu\text{mol/L}$.

[0070] Preferred products or compositions as described herein comprise frozen, freeze-dried, lyophilized (e.g. lyophilized powder), or dried bacteria and are preferably in a unit-dosage format, e.g. a capsule (e.g. gelatin capsule) or tablet or gel or sachet. Appropriate ratios and doses (e.g. in the form of numbers of bacteria or CFUs) for use in such products, etc., are described elsewhere herein and in the Examples. Other components may also be included in such products, etc., for example preservatives (e.g. glycerol), desiccants, stabilizers, gelling agents and/or cryoprotectants. In some embodiments such additional components are non-

natural agents. In some embodiments a prebiotic will be included. Examples of prebiotics are described elsewhere herein.

[0071] In one embodiment of the invention, a probiotic bacteria strain or strain combination described herein can be in the form of a capsule or a sachet or other suitable forms and can be orally administered to the mammal (or subject). In some embodiments, the administration can be one, two or three times/day and last for one, two or three months or as long as said mammal continues to suffer from the disease being treated.

[0072] Appropriate doses of the species or strains for use in the invention can be chosen depending on the disease to be treated, the mode of administration and the formulation concerned. For example, a dosage and administration regime is chosen such that the probiotic bacteria (or combination of bacteria) administered to the subject in accordance with the present invention can result in a therapeutic or health benefit. Thus, in embodiments of the invention where two or more different strains of bacteria are administered, an appropriate dose of each bacteria is selected such that a therapeutic or health benefit is observed when all strains are present. For example, daily doses of one or each bacteria of 10^4 to 10^{12} , for example 10^5 to 10^{10} , or 10^6 to 10^8 , or 10^7 to 10^9 , or 10^8 to 10^{10} total CFUs of bacteria may be used. A preferred daily dose of one or each bacteria is around 10^8 or 10^9 total CFUs, e.g. 10^7 to 10^{10} or 10^8 to 10^{10} or 10^8 to 10^9 . Such doses can be in the form of CFU/g or CFU/unit-dosage form (e.g. per sachet, capsule, tablet, etc).

[0073] Exemplary regimes are provided in the Examples.

[0074] The methods and uses of the invention can be carried out on any animal or subject or patient. In some embodiments, an animal or subject can be a mammal. In representative embodiments, the animal or subject can be a human.

[0075] Thus, in some embodiments, a method of treating or reducing the risk of intrahepatic cholestasis in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of a composition comprising at least one bacterial species or strain comprising bile acid deconjugation/hydrolysis activity and/or 7-epimerization activity, thereby treating or reducing the risk of intrahepatic cholestasis in a subject in need thereof.

[0076] Thus, viewed alternatively, the present invention provides a composition comprising at least one bacterial species or strain comprising bile acid deconjugation/hydrolysis activity and/or 7-epimerization activity, for use in a method of treating or reducing the risk of intrahepatic cholestasis in a subject.

[0077] Viewed alternatively, the present invention also provides the use of a composition comprising at least one bacterial species or strain comprising bile acid deconjugation/hydrolysis activity and/or 7-epimerization activity for the manufacture of a medicament (or composition) for treating or reducing the risk of intrahepatic cholestasis in a subject.

[0078] In some embodiments, a method of modulating bile acid level, e.g. serum bile acid level, in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of a composition comprising at least one bacterial species or strain comprising bile acid deconjugation/hydrolysis activity and/or 7-epimerization activity, thereby modulating bile acid level, e.g. serum bile acid level, in a subject in need thereof. In particular

embodiments, the subject has or is at risk of developing cholestasis, intrahepatic cholestasis (e.g., intrahepatic cholestasis of pregnancy), gall stones, the treatment of biliary dyspepsia, primary biliary cirrhosis, primary sclerosing cholangitis, chronic active hepatitis, hepatitis C, and/or other related liver diseases.

[0079] Thus, viewed alternatively, the present invention provides a composition comprising at least one bacterial species or strain comprising bile acid deconjugation/hydrolysis activity and/or 7-epimerization activity, for use in a method of modulating bile acid level, e.g. serum bile acid level, in a subject. In particular embodiments, the subject has or is at risk of developing cholestasis, intrahepatic cholestasis (e.g., intrahepatic cholestasis of pregnancy), gall stones, the treatment of biliary dyspepsia, primary biliary cirrhosis, primary sclerosing cholangitis, chronic active hepatitis, hepatitis C, and/or other related liver diseases.

[0080] Viewed alternatively, the present invention also provides the use of a composition comprising at least one bacterial species or strain comprising bile acid deconjugation/hydrolysis activity and/or 7-epimerization activity for the manufacture of a medicament (or composition) for modulating bile acid level, e.g. serum bile acid level, in a subject. In particular embodiments, the subject has or is at risk of developing cholestasis, intrahepatic cholestasis (e.g., intrahepatic cholestasis of pregnancy), gall stones, the treatment of biliary dyspepsia, primary biliary cirrhosis, primary sclerosing cholangitis, chronic active hepatitis, hepatitis C, and/or other related liver diseases.

[0081] In preferred embodiments, such modulation or modulating is by way of a reduction or decrease in bile acid level.

[0082] Thus, a yet further embodiment of the present invention provides a method of treating or reducing the risk of developing cholestasis, intrahepatic cholestasis (e.g., intrahepatic cholestasis of pregnancy), gall stones, the treatment of biliary dyspepsia, primary biliary cirrhosis, primary sclerosing cholangitis, chronic active hepatitis, hepatitis C, and/or other related liver diseases, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising at least one bacterial species or strain comprising bile acid deconjugation/hydrolysis activity and/or 7-epimerization activity, thereby treating or reducing the risk of said disease in a subject in need thereof.

[0083] Thus, viewed alternatively, the present invention provides a composition comprising at least one bacterial species or strain comprising bile acid deconjugation/hydrolysis activity and/or 7-epimerization activity, for use in a method of treating or reducing the risk of developing cholestasis, intrahepatic cholestasis (e.g., intrahepatic cholestasis of pregnancy), gall stones, the treatment of biliary dyspepsia, primary biliary cirrhosis, primary sclerosing cholangitis, chronic active hepatitis, hepatitis C, and/or other related liver diseases, in a subject.

[0084] Viewed alternatively, the present invention also provides the use of a composition comprising at least one bacterial species or strain comprising bile acid deconjugation/hydrolysis activity and/or 7-epimerization activity for the manufacture of a medicament (or composition) for treating or reducing the risk of developing cholestasis, intrahepatic cholestasis (e.g., intrahepatic cholestasis of pregnancy), gall stones, the treatment of biliary dyspepsia,

primary biliary cirrhosis, primary sclerosing cholangitis, chronic active hepatitis, hepatitis C, and/or other related liver diseases, in a subject.

[0085] In some embodiments, a method of treating or reducing the risk of pruritis in a subject in need thereof is provided, comprising administering to the subject a therapeutically effective amount of a composition comprising at least one (probiotic) bacterial species or strain comprising bile acid deconjugation/hydrolysis activity and/or 7-epimerization activity. In particular embodiments, the subject has or is at risk of developing cholestasis, intrahepatic cholestasis (e.g., intrahepatic cholestasis of pregnancy), gall stones, the treatment of biliary dyspepsia, primary biliary cirrhosis, primary sclerosing cholangitis, chronic active hepatitis, hepatitis C, and/or other related liver diseases.

[0086] Thus, viewed alternatively, the present invention provides a composition comprising at least one bacterial species or strain comprising bile acid deconjugation/hydrolysis activity and/or 7-epimerization activity, for use in a method of treating or reducing the risk of pruritis in a subject. In particular embodiments, the subject has or is at risk of developing cholestasis, intrahepatic cholestasis (e.g., intrahepatic cholestasis of pregnancy), gall stones, the treatment of biliary dyspepsia, primary biliary cirrhosis, primary sclerosing cholangitis, chronic active hepatitis, hepatitis C, and/or other related liver diseases.

[0087] Viewed alternatively, the present invention also provides the use of a composition comprising at least one bacterial species or strain comprising bile acid deconjugation/hydrolysis activity and/or 7-epimerization activity for the manufacture of a medicament (or composition) for treating or reducing the risk of pruritis in a subject. In particular embodiments, the subject has or is at risk of developing cholestasis, intrahepatic cholestasis (e.g., intrahepatic cholestasis of pregnancy), gall stones, the treatment of biliary dyspepsia, primary biliary cirrhosis, primary sclerosing cholangitis, chronic active hepatitis, hepatitis C, and/or other related liver diseases.

[0088] In some embodiments, the pruritis is associated with, e.g. is a symptom of or is a side-effect of, one or more of these diseases. In particular, such pruritis can be associated with intrahepatic cholestasis, preferably intrahepatic cholestasis of pregnancy.

[0089] In some embodiments, intrahepatic cholestasis comprises intrahepatic cholestasis of pregnancy.

[0090] In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In representative embodiments, the subject is a human female, for example a pregnant human female.

[0091] Any appropriate bacterial species or strain, for example any appropriate probiotic bacterial species or strain, can be used in the methods or uses of the present invention, providing they have the functional properties as described herein.

[0092] Use of at least one bacterial species or strain in combination is particularly preferred in the methods and uses of the present invention (for example 1, 2, 3, 4, or 5 species or strains may be used). In embodiments where more than one strain is used then such strains can be of the same or different species of bacteria. Equally, more than one species of bacteria can be used in certain embodiments.

[0093] It can be seen that in some embodiments of the invention, a combination or mixture of bacterial strains or

species are administered (combination therapy). Such mixtures or combinations of bacteria can be administered together in a single (the same) composition or administered separately (e.g. in different products or compositions). If administered separately then such administration may be sequential or simultaneous. However, the separate administration forms part of the same therapeutic regimen or method.

[0094] In embodiments where the administration of the two or more strains or species is separate or sequential, it is preferred that the administrations are made within a reasonable time frame of each other as described elsewhere herein. For example, the separate administrations are preferably made within hours (e.g. one hour) or minutes (e.g. within 15 or 30 minutes) of each other, most preferably within as short a timeframe as possible (including simultaneous or effectively simultaneous administration). Preferably the two or more strains or species of bacteria are co-administered in a single composition.

[0095] In embodiments where more than one strain of probiotic bacteria is used in a mixture in a single composition, or where more than one strain of probiotic bacteria is used but they are administered separately, then any appropriate ratio of the bacteria can be used providing that the desired function of the strains (for example bile acid deconjugation/hydrolysis activity or 7-epimerization activity or sulphate reducing activity) is retained to a useful extent.

[0096] Such ratios can readily be determined by a person skilled in the art. For example, such a combination of two or more strains or species might be used at a ratio of 1:10, 1:5, 1:1, 5:1, or 10:1 or anywhere between these extremes, e.g. 1:1. Such ratios may also be used in the products, kits, compositions, etc., of the invention as described elsewhere herein. Such species or strains are generally isolated species or strains, or pure cultures, which can then be mixed together if a combination of species or strains is used. In some embodiments such strains will not correspond to naturally occurring strains.

[0097] In some embodiments, the at least one bacterial species or strain comprises at least two bacterial species or strains, the at least two bacterial species or strains comprising a first bacterial species or strain comprising bile acid deconjugation/hydrolysis activity and a second bacterial species or strain comprising 7-epimerization activity.

[0098] In some embodiments, the at least one bacterial species or strain comprises at least three bacterial species or strains, the at least three bacterial species or strains comprising a first bacterial species or strain comprising bile acid deconjugation/hydrolysis activity, a second bacterial species or strain comprising 7 α -hydroxysteroid dehydrogenase (HSDH) activity, and a third bacterial species or strain comprising 7 β -HSDH activity.

[0099] In some embodiments, the composition may further comprise at least one bacterial species or strain comprising sulfate reducing activity. This activity may be provided by one or more of the same bacterial species or strains which provide the bile acid deconjugation or 7-epimerization activity or may be provided by at least one additional (or different) bacterial species or strain. In some embodiments, the bacterial species or strain comprising sulfate reducing activity may be *Desulfovibrio piger* DSM 32187. This strain of *Desulfovibrio piger* for use in the present invention has been deposited under the Budapest Treaty at DSMZ (Leibniz Institute DSMZ—German Collection of Microorganisms

and Cell Cultures, Inhoffenstr. 7B, D-38124 Braunschweig, Germany) on October 20, 2015.

[0100] In some embodiments, the bacterial species or strain comprising the activity of bile acid deconjugation/hydrolysis activity may be a bifidobacteria. In representative embodiments, the bacterial species or strain comprising the activity of bile acid deconjugation/hydrolysis activity may be *Bifidobacterium longum* ATCC BAA-999.

[0101] In some embodiments, the bacterial species or strain comprising 7-epimerization activity may be *Clostridium baratii* ATCC 27638.

[0102] In some embodiments, the bacterial species or strain comprising 7 α -HSDH activity may be *Bacteroides fragilis* ATCC 25285 and/or *Bacteroides thetaiotaomicron* DSM 2079, and/or the bacterial species or strain comprising 7 β -HSDH activity may be *Collinsella aerofaciens* ATCC 25986.

[0103] In some embodiments, a composition comprising at least one bacterial strain or species comprises *Bifidobacterium longum* ATCC BAA-999, *Bacteroides fragilis* ATCC 25285, and *Collinsella aerofaciens* ATCC 25986.

[0104] In some embodiments, a composition comprising at least one bacterial strain or species comprises *Bifidobacterium longum* ATCC BAA-999, *Bacteroides thetaiotaomicron* DSM 2079, and *Collinsella aerofaciens* ATCC 25986.

[0105] In some embodiments, a composition comprising at least one bacterial strain or species comprises *Bifidobacterium longum* ATCC BAA-999 and *Clostridium baratii* ATCC 27638.

[0106] In some embodiments, a composition comprising at least one bacterial strain or species comprises *Bifidobacterium longum* ATCC BAA-999, *Bacteroides fragilis* ATCC 25285, *Collinsella aerofaciens* ATCC 25986, and *Desulfovibrio piger* DSM 32187.

[0107] In some embodiments, a composition comprising at least one bacterial strain or species comprises *Bifidobacterium longum* ATCC BAA-999, *Bacteroides thetaiotaomicron* DSM 2079, *Collinsella aerofaciens* ATCC 25986 and *Desulfovibrio piger* DSM 32187.

[0108] In some embodiments, a composition comprising at least one bacterial strain or species comprises *Bifidobacterium longum* ATCC BAA-999, *Clostridium baratii* ATCC 27638 and *Desulfovibrio piger* DSM 32187

In some embodiments, the method of the invention further comprises administering to the subject a prebiotic, for example in the form of a composition comprising a therapeutically effective amount of a prebiotic. In some embodiments, the prebiotic is administered prior to, concurrently with, or after administration of the probiotic bacteria. In some embodiments, the prebiotic may be inulin. Other examples of prebiotics are described elsewhere herein.

[0109] The prebiotic may be in the same composition as the probiotic bacteria or administered separately, for example in a different composition.

EXAMPLES

[0110] The present invention will now be described with reference to the following examples. It should be appreciated that these examples are for the purpose of illustrating aspects of the present invention, and do not limit the scope of the invention as defined by the claims.

Example 1

[0111] A product (Product A) is developed and contains the following bacterial strains:

[0112] 1) *Bifidobacterium longum* ATCC BAA-999

[0113] 2) *Clostridium baratii* ATCC 27638

[0114] 3) *Desulfovibrio piger* DSM 32187

The bacterial strains in the product are in the concentration of 1×10^8 cfu/g/bacterial strain and in the form of lyophilized powder in standard gelatin capsules of 500 mg.

Example 2

[0115] A product (Product B) is developed and manufactured in the form of a sachet containing a composition of:

[0116] 1) *Bifidobacterium longum* ATCC BAA-999: 1×10^8 cfu/sachet

[0117] 2) *Bacteroides fragilis* ATCC 25285: 1×10^8 cfu/sachet

[0118] 3) *Collinsella aerofaciens* ATCC 25986: 1×10^8 cfu/sachet

[0119] 4) Inulin: 3000 mg/sachet

[0120] The composition is filled at ambient temperature into aluminum foil bags as known in the art with desiccant (10 cm \times 12 cm, using packaging material PET12/PE/ALU 12/PE/PE+desiccant/PE from Alcan) in a LAF bench (Holten Laminair Model S-2010 1.2 from Heto-Holten A/S, Denmark). To each bag, 3 g of powder with *B. longum* ATCC BAA-999, *B. fragilis* ATCC 25285 and *C. aerofaciens* ATCC 25986 and inulin is added using the balance XP-600 from Denver Instrument GmbH, Germany. The filled aluminum foil bags are then heat sealed with the film sealing device model F460/2 from Kettenbaum Folienschweisstechnik GmbH & Co. KG, Germany.

Example 3

[0121] A test group of pregnant women with mild ICP (bile acid levels ≥ 10 μ mol/L and ≥ 40 μ mol/L) is included in a study and receive the probiotic Product B (as described in Example 2). The treatment takes place three times/day and lasts for three months or until delivery of the baby. Prior to the treatment the women is examined by obtaining blood samples and by registering the percept severity of pruritus/itching. Blood samples is analysed with regards to concentration of bile acids.

[0122] After treatment, the women are examined once again as described above. Women that are treated with the probiotic Product B show decreased levels of bile acids in the blood and experience a relief in pruritus/itching.

[0123] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

1-21. (canceled)

22. A method of treating or reducing the risk of intrahepatic cholestasis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising at least one bacterial strain comprising bile acid deconjugation activity and/or 7-epimerization activity, thereby treating or reducing the risk of intrahepatic cholestasis in the subject in need thereof.

23-30. (canceled)

31. The method of claim 22, wherein treating or reducing the risk of intrahepatic cholestasis in the subject comprises treating or reducing the risk of pruritis.

32. The method of claim 22, wherein the intrahepatic cholestasis comprises intrahepatic cholestasis of pregnancy.

33. The method of claim 22, wherein the at least one bacterial strain comprises at least two bacterial strains, the at least two bacterial strains comprising a first bacterial strain comprising bile acid deconjugation activity and a second bacterial strain comprising 7-epimerization activity.

34. The method of claim 22, wherein the at least one bacterial strain comprises at least three bacterial strains, the at least three bacterial strains comprising a first bacterial strain comprising bile acid deconjugation activity, a second bacterial strain comprising 7 α -hydroxysteroid dehydrogenase (HSDH) activity, and a third bacterial strain comprising 7 β -HSDH activity.

35. The method of claim 22, wherein the composition further comprises one or more bacterial strains comprising sulfate reducing activity, optionally, the one or more bacterial strains comprising sulfate reducing activity is *Desulfovibrio piger* DSM 32187.

36. The method of claim 33, wherein the composition further comprises one or more bacterial strains comprising sulfate reducing activity, optionally, the one or more bacterial strains comprising sulfate reducing activity is *Desulfovibrio piger* DSM 32187.

37. The method of claim 34, wherein the composition further comprises one or more bacterial strains comprising sulfate reducing activity, optionally, the one or more bacterial strains comprising sulfate reducing activity is *Desulfovibrio piger* DSM 32187.

38. The method of claim 22, wherein the bacterial strain comprising the bile acid deconjugation activity is *Bifidobacterium longum* ATCC BAA-999 and the bacterial strain comprising 7-epimerization activity is *Clostridium baratii* ATCC 27638.

39. The method of claim 33, wherein the bacterial strain comprising the bile acid deconjugation activity is *Bifido-*

bacterium longum ATCC BAA-999 and the bacterial strain comprising 7-epimerization activity is *Clostridium baratii* ATCC 27638.

40. The method of claim 34, wherein the bacterial strain comprising 7 α -HSDH activity is *Bacteroides fragilis* ATCC 25285 and/or *Bacteroides thetaiotaomicron* DSM 2079.

41. The method of claim 34, wherein the bacterial strain comprising 7 β -HSDH activity is *Collinsella aerofaciens* ATCC 25986.

42. The method of claim 34, wherein the composition comprises *Bifidobacterium longum* ATCC BAA-999, *Bacteroides fragilis* ATCC 25285, and *Collinsella aerofaciens* ATCC 25986.

43. The method of claim 34, wherein the composition comprises *Bifidobacterium longum* ATCC BAA-999, *Bacteroides thetaiotaomicron* DSM 2079, and *Collinsella aerofaciens* ATCC 25986.

44. The method of claim 35, wherein the composition comprises *Bifidobacterium longum* ATCC BAA-999, *Clostridium baratii* ATCC 27638 and *Desulfovibrio piger* DSM 32187.

45. The method of claim 36, wherein the composition comprises *Bifidobacterium longum* ATCC BAA-999, *Bacteroides thetaiotaomicron* DSM 2079, *Collinsella aerofaciens* ATCC 25986 and *Desulfovibrio piger* DSM 32187.

46. The method of claim 37, wherein the composition comprises *Bifidobacterium longum* ATCC BAA-999, *Bacteroides fragilis* ATCC 25285, *Collinsella aerofaciens* ATCC 25986, and *Desulfovibrio piger* DSM 32187.

47. The method of claim 22, further comprising administering to the subject a prebiotic.

48. The method of claim 47, wherein the prebiotic is inulin.

49. The method of claim 22, wherein the subject is a mammal.

50. The method of claim 22, wherein the subject is a human.

* * * * *